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HEART FAILURE IN OLDER PERSONS: 
CONSIDERATIONS FOR THE PRIMARY 
CARE PHYSICIAN
Heart failure (HF) affects over 500,000Canadians, with 50,000 new patientsdiagnosed each year.1,2 While mortality
from cardiovascular diseases has progressively
declined in Canada,3 the burden of HF is expected
to continue rising as a result of population aging
and improved survival of patients with other
cardiovascular diseases.4 HF is the leading cause
of hospitalization and death among those aged 65
years and over,3 with a mortality rate of up to 50%
within 5 years of diagnosis.1 Elderly HF patients
are complex: a recent Ontario study of home care
recipients with HF found that these clients had
more health instability, took more medications,
and had more co-morbidities compared with
other home care clients.5
Optimal management of HF in “complex seniors”
requires that clinicians understand the
interactions between HF and age-associated
syndromes such as frailty, cognitive impairment,
and functional decline.1,6 As the majority of
Canadian patients with HF are treated by primary
care providers (PCPs),7 this article is directed at
PCPs caring for older adults with HF. It is meant
as a brief overview and discusses how the
Canadian Cardiovascular Society (CCS)
Consensus Guidelines on HF can be applied in
daily practice (Table 1).1,8–13
What Is Heart Failure?
HF is a syndrome that results when abnormal
heart function leads to clinical manifestations of
low cardiac output and/or pulmonary or systemic
congestion.14 The main conditions associated with
the development of HF are coronary heart disease
(CHD) and hypertension.14,15 HF patients with a
left ventricular ejection fraction (LVEF) <45% are
defined as having HF with reduced ejection
fraction (HFREF), whereas HF patients with a
LVEF ≥45% are considered to have HF with
preserved ejection fraction (HFPEF). Recent data
suggest that HFPEF may be as common as HFREF
among seniors and that both conditions may be
associated with similar outcomes.16–18
Considerations in Older Patients
PCPs are uniquely positioned to diagnose HF in
its earlier stages. The diagnosis of HF is primarily
established on clinical grounds. It is important to
perform a good history and physical examination.
Chest radiography is recommended, though it has
in the primary care setting modest specificity and
sensitivity for pulmonary edema.19,20 Further-
more, diagnosing and managing HF can be
complicated in older outpatients with con-
comitant co-morbidities such as frailty or
cognitive impairment.6,15,21–23
Table 1. Canadian Cardiovascular Society (CCS) Guidelines*
2011 Update8 “Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal 
Dysfunction, Mechanical Circulatory Support, and Palliative Care”
2010 Update9 “Heart Failure in Ethnic Minority Populations, Heart Failure and Pregnancy, 
Disease Management, and Quality Improvement/Assurance Programs”
2009 Update10 “Diagnosis and Management of Right-Sided Heart Failure, Myocarditis, Device 
Therapy and Recent Important Clinical Trials”
2008 Update11 Best practices for Transition of Care of Heart Failure Patients, and the Recognition,
Investigation and Treatment of Cardiomyopathies”
2007 Update12 “Prevention, Management during Intercurrent Illness pr Acute Decompensation, 
and Use of Biomarkers”
2006 Guideline1 “Diagnosis and Management”
2002/2003 Update13 “Consensus Conference Update for the Diagnosis and Management of Heart 
Failure”
*Since 2005, the CCS has implemented a “closed loop” model to support knowledge translation in cardiovascular care,
accommodating end-user and stakeholder input and evaluation on an ongoing basis, and thus allowing the CCS to continually
improve and expand the breadth and utility of guidelines. The first CCS guideline to which the model was applied was heart
failure. Since 2005, there have been six CCS heart failure guideline updates that have been informed by feedback from end
users. For more information on the HF guideline program please visit http://www.ccs.ca/guidelines/cc_library_e.aspx.
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Frailty arises from the accumulation over time of deficits across
multiple physiological systems, and leads to decreased homeostatic
reserve, loss of resistance to health stressors, and a greater vulnerability
to poor health outcomes.24 Frailty can affect between 25 and 50% of
patients with cardiovascular disease,25 particularly older patients with
HF.26 Frail HF patients are at greater risk of hospitalization and
functional decline compared with their non-frail counterparts.21,25
Frail and functionally impaired seniors are more likely to manifest
atypical signs and symptoms (Table 2).22,23
Older patients with HF have an increased risk of cognitive impairment
(CI), including dementia.27–31 Older patients hospitalized with HF
exacerbation can also present with acute and fluctuating CI due to
delirium.32 CI in HF patients has been associated with an increased
risk of non-adherence to treatment, accelerated functional decline,
increased hospitalization, and increased mortality.33,34 Recent data
suggest that even mild CI, defined either as a Mini-Mental State
Examination (MMSE) score <28/30, or a Montreal Cognitive
Assessment (MoCA) score of 23 or less, may be associated with worse
self-care ability and adverse outcomes in older persons with HF.35–38
Psychiatric symptoms, such as anxiety or depression, may also be
associated with symptomatic or undertreated HF among frail
seniors.39 Orthopnea and paroxysmal nocturnal dyspnea are more
specific symptoms of HF that may not become apparent until
relatively late in the course of an HF exacerbation; however, these
symptoms may manifest as non-specific sleep disturbances. In
addition, many of the physical signs of HF can also occur in other
diseases that are common in older patients.15 Exertional dyspnea may
occur as a result of pulmonary disease, obesity, or deconditioning.
Individuals with HF and who are sedentary may not experience
exertional dyspnea, and dependent edema may accumulate over the
sacrum rather than at the ankles.6
Assessing Older Patients with HF
A complete history and physical examination should be conducted to
assess any senior presenting with classic clinical features of HF, or the
recent development of atypical symptoms or geriatric syndromes.6 For
most seniors, collateral information from an informal caregiver should
be sought.21 Transthoracic echocardiography is the modality of choice
to assess the heart and should be performed in all patients with
suspected HF. Routine hematological, renal, electrolyte, and thyroid
indices should be assessed to rule out factors contributing to the HF
syndrome or that could complicate its management. If available,
plasma natriuretic peptides such as brain natriuretic peptide (BNP)
can be useful to rule out HF if they are normal, or to rule in HF when
the clinical diagnosis is in doubt.12 A chest radiograph should be
obtained looking for evidence of pleural effusions, vascular
redistribution, or interstitial or alveolar edema. A normal
electrocardiogram makes a diagnosis of HF unlikely, and while it is
not specific for HF, it can identify the presence of underlying
conditions, such as CHD or arrhythmias, that can exacerbate or
precipitate HF.40
Once HF is diagnosed, it is important to characterize a patient’s
functional capacity. Such information is useful to follow patient
progress and guiding therapeutic choices. The New York Heart
Association (NYHA) Functional Classification is commonly used for
this purpose and consists of four categories based on the presentation
of symptoms in relation to activity.41 Concerns have been raised about
the reliability of the NYHA classification in older HF patients, who
might be more appropriately assessed using items and subscales from
instruments such as the Resident Assessment Instrument (RAI) 2.0.42
Clinicians should consider screening older HF patients for CI, using
an instrument such as the MoCA, and for frailty, using, for example,
the Canadian Study of Health and Aging (CSHA) frailty scale.1,36,43 For
cognitively impaired HF patients, identifying and educating a capable
caregiver who can help with self-monitoring, medication adherence,
and lifestyle modifications such as fluid management and meal
preparation are strongly recommended.
Management
Pharmacological Therapy
The most recent CCS recommendations for the pharmacological
treatment of HF are presented in Figure 1 and Table 3. While most of
these recommendations are derived from large clinical trials that
generally exclude frail seniors, evidence from several small randomized
trials and multiple observational studies suggest that they also apply
to older patients.1,44–46 However, HF therapies remain underprescribed
for older patients. Among home care clients with HF in Ontario,
28.6% received no first-line pharmacotherapy and only 28.0% received
the recommended combination therapy of angiotensin-converting
enzyme inhibitors (ACEIs) and β-blockers (Figure 2).47 Reasons why
Table 2. Signs and Symptoms of Heart Failure
Classic Features of HF
Dyspnea
Orthopnea
Paroxysmal nocturnal dyspnea
Fatigue
Weakness
Exercise intolerance
Dependent edema
Cough
Weight gain
Abdominal distension
Nocturia
Cool extremities
HF = heart failure.
Atypical Clinical Features of HF in Frail Seniors
Delirium/new or worsening confusion
Falls
Sudden functional decline
Sleep disturbances
Nocturia or nocturnal incontinence
Dyspnea less likely if patient is sedentary
Ankle edema may reflect venous insufficiency, drug effects, immobility, or
malnutrition
Sacral edema
Pulmonary rales/crackles are nonspecific
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Table 3. Drug Therapy in Heart Failure
Drug Start Dose (mg) Target Dose (mg)
ACEIs
Captopril 6.25–12.5 tid 25–50 tid
Enalapril 1.25–2.5 bid 10 bid
Ramipril 1.25–2.5 od–bid 5 bid or 10 od
Lisinopril 2.5–5 od 20–35 od
Perindopril 2–4 od 4–8 od
Trandolapril 1–2 od 4 od
β-blockers
Carvedilol 3.125 bid 25 bid
Bisoprolol 1.25 od 10 od
Metoprolol CR/XL 12.5–25 od 200 od
ARBs
Candesartan 4 od 32 od
Valsartan 40 bid 160 bid
Aldosterone antagonists
Spironolactone 12.5 od 50 od
Eplerenone 25 od 50 od
Loop diuretics
Furosemide
Metolazone
Bumetanide
Vasodilators
Isosorbide dinitrate 10 tid 40 tid
Hydralazine 37.5 tid 40 tid
Practical Tips
• Prescribe early in course of HF, starting at a low dose and titrating to target 
or highest tolerable dose.
• Closely monitor for renal dysfunction and hyperkalemia, especially during 
acute dehydrating illness.
• Prescribe early in course of HF, starting at a low dose and titrating to target 
or highest tolerable dose.
• Avoid sudden major dose reduction or abrupt withdrawal.
• Delay use until resolution of any pulmonary edema.
• Avoid in patients with severe reactive airway disease, symptomatic 
bradycardia, or significant AV block. 
• Prescribe early in course of HF, starting at a low dose and titrating to target 
or highest tolerable dose.
• Closely monitor for renal dysfunction and hyperkalemia, especially during 
acute dehydrating illness.
• Aldosterone antagonists are not intended to be used as diuretics, and exceeding 
recommended doses may lead to complications of hyperkalemia.
• Closely monitor for renal dysfunction and hyperkalemia, especially during 
acute dehydrating illness.
• Consider reducing dose if patient is patient is otherwise stable, the lowest 
minimal dose should be used.
• Before and after introduction, or significant increase in dose, blood work
should be checked for electrolytes and renal function.
• Serum potassium should be maintained at 4 mmol/L or greater.
• Serum magnesium and calcium should be checked if ventricular arrhythmias or 
muscle cramps occur.
• Some patients can be taught how to adjust their diuretic dose based on symptoms.
• Metolazone should be used sparingly in combination with furosemide; 
continuous use may result in rapid and profound volume depletion.
• Avoid continuous use of nitrates as most patients develop tolerance.
• Calcium channel blockers and α-blockers are NOT used as a primary 
therapy for HF but may have other specific indications in selected patients 
(e.g., angina).
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; AV = atrioventricular; bid = twice daily; HF = heart failure; od = once daily; tid = thrice daily.
physicians are reticent to prescribe recommended HF therapies include
diagnostic uncertainty, concerns over adverse drug events (ADEs),
patient non-adherence, and a lack of awareness of research evidence
relevant to seniors.48,49
HF with Reduced Ejection Fraction
For patients with HFREF, first-line combination therapy consists of an
ACEI and a β-blocker, unless specific contraindications to either drug
exist. There is overwhelming evidence demonstrating that these
medications reduce the risks of death, hospitalization, dyspnea, and
improve function as well as quality of life.50–53 ACEIs may be especially
beneficial in frail seniors for preserving physical and cognitive
functions.39,45,54,55 Angiotensin receptor blockers (ARBs) have not been
shown to be more effective than ACEIs and are thus recommended for
patients who are truly intolerant of ACEIs.56 Patients intolerant of ACEIs
and ARBs may be considered for combination nitrate and hydralazine
therapy.1
Patients with persistent symptoms despite optimal doses of first-line
drugs may benefit from additional therapies. Aldosterone antagonists
such as spironolactone and eplerenone are indicated in patients with
LVEF <35% and NYHA III–IV HF, and in high-risk patients with
persistent NYHA II symptoms.1 ARBs may be considered as add-on
therapy to ACEIs in patients with persistent NYHA II–IV symptoms.
When patients experience repeat HF hospitalizations, digoxin therapy
may be considered. Digoxin dosing should be adjusted for creatinine
clearance in order to achieve 8- to 12-hour post-dosage serum levels of
1 ng/mL.1 Medically optimized older patients with HFREF and LVEF
<30%, and who are otherwise healthy and functionally independent,
should be considered for insertion of an implantable cardiac
defibrillator if such an intervention is compatible with their advance
care plans. Older HF patients with LVEF <30% and a QRS interval
>120 ms should be considered for referral for cardiac
resynchronization therapy. Loop diuretics, nitrates, and vasodilators
may be considered if additional symptom control is required.
HF with Preserved Ejection Fraction
There is a paucity of clinical trial evidence to guide the management
of patients with HFPEF, and the few trials that have been conducted
in this area suggest that, at best, treatment with ACEIs, ARBs, or 
β-blockers may be associated with fewer hospitalizations.57
Hypertension is the most common underlying etiology of HFPEF and,
therefore, if present, should be treated optimally. Rate control of any
arrhythmia is paramount to permit diastolic filling, and loop diuretics
can be used to control pulmonary congestion and peripheral edema.
Optimal Prescribing for Patients with HF
In seniors with multiple co-morbidities, adherence to the HF
guidelines inevitably leads to polypharmacy, an increased risk of
ADEs, and poor medication adherence. Certain medications can
exacerbate HF and should be avoided (Table 4). Cognitive enhancers
should be prescribed with caution. Acetylcholinesterase inhibitors can
exacerbate cardiac conduction problems and lead to syncope.58
Despite oft-cited concerns about hypotension and renal and
electrolyte abnormalities, HF medications can be used safely in older
patients. Medications may need to be introduced in lower doses and
titrated more slowly. In order to maximize clinical benefit, medications
doses should be titrated to those shown to be effective in clinical trials,
or to the highest dose tolerated by an individual patient.1,59 In general,
cough, symptomatic hypotension, bradycardia, or renal and electrolyte
disorders can be effectively managed without having to discontinue
medications. Table 5 offers troubleshooting tips to optimize
prescribing for HF patients. Adherence can be enhanced by prescribing
once-daily drug formulations; using dosettes, blister packs, or similar
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Figure 1. Algorithm for prevention and treatment of clinically stable heart failure.
ACE-I/ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CRT = cardiac resynchronization therapy; ICD = implantable cardiac defibrillator; HF
= heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RF = reduced ejection fraction; Rx = prescription; S&S = signs and symptoms.
Reproduced with permission. 
Table 4. Medications to Avoid in Patients with Heart Failure
Drug Class Effect
Older-generation calcium channel blockers (nifedipine, verapamil, diltiazem) Negative inotropes
Thiazolidinediones (glitazones) Cause fluid retention
Antiarrhythmic agents (especially flecainide, negative inotropic effect Negative inotropic effect
propafenone, disopyramide, and calcium channel blockers, and less so for 
amiodarone, dofetilide, and ibutilide)
Doxorubicin Direct cardiotoxic effect
Nonsteroidal anti-inflammatory drugs, including cyclooxygenase-2 inhibitors Fluid retention
devices; as well as involving and educating caregivers in daily
monitoring strategies. 
Non-pharmacological Interventions
Regular physical activity is recommended for all stable HF patients,
other than those with NYHA IV symptoms.1 Referral of older HF
patients to a cardiac rehabilitation program should be strongly
considered. Participants should undergo a graded exercise stress test
to assess functional capacity and determine target heart rates for
training. Exercise programs should aim to achieve moderate aerobic
and strength training exercises three to five times per week for 30–45
minutes. If such programs are not suitable, more frail HF patients
should be referred to regular exercise programs that target aerobic
capacity, strength, and balance and that are tailored to their needs and
limitations, in order to prevent deconditioning and promote
independence.
Restriction of salt intake is recommended to prevent worsening of HF
symptoms.1 Recent evidence suggests that 3 g/d or less of sodium can
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Figure 2. Mechanism of action and benefits of angiotensin-converting enzyme inhibitors and β-blockers.
ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; PKA = protein kinase A.
prevent adverse events in patients with NYHA class III/IV HF, and
another study found lower event rates in patients taking <2.8 g/d.60,61
These studies were conducted in prospective cohorts of community-
dwelling patients aged on average in their mid-60s and primarily with
HFREF, though their results are likely equally applicable to patients
with HFPEF. Regular weights, ideally obtained daily, allow for the early
recognition of decompensated HF, often days or weeks prior to the
onset of shortness of breath.62,63
HF and Disease Management
Referral of older HF patients to disease management programs should
be considered.64 Discharge of hospitalized seniors with HF should be
facilitated by transitional care programs.65–67 Referral of cognitively
impaired or frail older HF patients to specialized geriatric services
should be considered. However, continued involvement of and
collaboration with PCPs is essential. The reorganization of primary
care into multidisciplinary teams, as exemplified by the Family Health
Team model in Ontario, has shown promising results in the
management of chronic diseases such as dementia68 and, thus, has the
potential to also improve the care of HF.
End-of-Life Planning and Care
HF has a highly variable illness trajectory and high prognostic
uncertainty. Patients with HF may die suddenly, often early in the
course of their illness, or follow a course of progressive decline
punctuated by acute exacerbations.9 Consequently, it is important to
start discussing end-of-life planning and care with patients early in
the course of their illness. The timing of discussions should strongly
consider the high mortality rate in the year following an HF
hospitalization.69 Advanced medical directives and a living will should
be discussed with patients as well as their identified surrogate decision
makers. 
Conclusion
HF is a common condition among older patients. The syndrome can
be complicated by geriatric syndromes such as frailty, functional
decline, and CI. Understanding the impact of these geriatric
syndromes on the assessment and management of HF is critical to
optimal delivery of care to these patients. The potential for clinical
improvements in the severity and expression of HF underscores the
importance of optimizing therapies in older patients. PCPs have an
important role to play in the management of aging HF patients, a role
that should continue to expand successfully.
This article has been peer reviewed.
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